The buyout rumors are heating up.
After the FDA granted approval for ACAD’s Parkinson’s disease Psychosis (PDP) treatment, the list of potential acquirers is getting longer.
Not only is Pfizer, Biotgen, and Teva reportedly interested in the company, but now reports are surfacing that AstraZeneca may be a potential bidder, too. Sources say ACADIA may not accept anything less than $60 a share for the company, according to a report from the UK Daily Mail.
At $40 a share, subscribers to The Cheap Investor are seeing potential gains of 3,710% and 3,128%. Should ACAD receive a bid of $60, potential gains could run as high as 5,669%. That would mean every $5,000 risked on our $1.05 recommendation, would be worth more than $285,000 inside six years.